AI Article Synopsis
- Antimicrobial dosing is challenging for patients on continuous renal replacement therapy (CRRT).
- This case discusses a patient treated with cefiderocol for multidrug-resistant pneumonia and bacteremia, receiving 2 g every 8 hours as a 3-hour infusion during CRRT.
- The article outlines the patient’s clinical progress and the pharmacokinetics of cefiderocol in their treatment.
Article Abstract
Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266675 | PMC |
| http://dx.doi.org/10.1093/ofid/ofab252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High rates of cefidercol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients.
Crit Care
December 2024
Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.
Curr Issues Mol Biol
December 2024
Department of Diagnostics and Public Health, Microbiology Section, Verona University, 37134 Verona, Italy.
Article Synopsis
- Novel antimicrobial drugs, like cefiderocol, have been developed to tackle the rise of antimicrobial resistance, specifically against multidrug-resistant (MDR) Gram-negative bacilli (GNB).
- Cefiderocol, a unique siderophore cephalosporin, efficiently penetrates bacterial outer membranes, making it effective against various resistance strategies and offering a broad spectrum of action.
- Despite its effectiveness, recently identified cefiderocol-resistant strains highlight the need for new strategies in clinical practice to maintain its antibacterial efficacy.
Optimal dosage regimens of cefiderocol administered by short, prolonged or continuous infusion: a PK/PD simulation study.
J Antimicrob Chemother
December 2024
Facultés de Médecine et de Pharmacie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Background And Objectives: Cefiderocol approved dosages are based on a prolonged infusion (PI) of 3 h that may not be adequate in all settings The objective of this study was to identify alternative cefiderocol dosage regimens based on short infusion (SI) or continuous infusion (CI).
Methods: We performed 1000-patient pharmacokinetic/pharmacodynamic (PK/PD) simulations based on a reference population model. Drug penetration into the epithelial lining fluid (ELF) was considered for pneumonia.
[Translated article] National survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life-support techniques: The DOSEBL study protocol.
Farm Hosp
December 2024
Servicio de Farmacia, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain; Grupo de investigación en Patología Infecciosa y Antimicrobianos (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Introduction: Infections caused by multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients present a challenge for timely and appropriate antibiotic treatment. This is particularly important in patients undergoing extracorporeal life-support techniques such as renal replacement therapy and extracorporeal membrane oxygenation. These techniques can introduce additional pharmacokinetic alterations, potentially leading to suboptimal exposure to antibiotics.
View Article and Find Full Text PDFDevelopment and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model.
J Antimicrob Chemother
December 2024
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Background: Murine pneumonia models play a fundamental role in the preclinical development of novel compounds seeking an indication for the treatment of pneumonia. It is vital that plasma exposures in these models are not used as a surrogate for exposure in pulmonary epithelial lining fluid (ELF). Herein, human-simulated regimens (HSRs) in both plasma and ELF of meropenem, cefiderocol and tobramycin are described in the standardized COMBINE murine neutropenic pneumonia model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!